VolitionRx Limited (VNRX) 10-Year Financial Performance & Capital Metrics

VNRX • • Industrial / General

HealthcareDiagnostics & ResearchCancer Diagnostics & Oncology TestingLiquid Biopsy & Circulating Tumor DNA

AboutVolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.Show more

Revenue $1M +59.1%
EBITDA -$26M +25.7%
Net Income -$27M +23.6%
EPS (Diluted) -0.31 +38.0%
Gross Margin 100%
EBITDA Margin -2082.35% +53.3%
Operating Margin -2190.9% +52.8%
Net Margin -2186.27% +52.0%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -79.40 +51.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 135.3%

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 10 (bottom 10%)
✗Shares diluted 21.5% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y55.64%

5Y135.32%

3Y139.28%

TTM14.48%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM23.41%

EPS CAGR

10Y-

5Y-

3Y-

TTM35.29%

ROCE

10Y Avg-183.84%

5Y Avg-233.28%

3Y Avg-304.68%

Latest-262.18%

Peer Comparison

Liquid Biopsy & Circulating Tumor DNA

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
BIAFbioAffinity Technologies, Inc.	6.39M	1.42	-0.06	269.75%	-217.5%	-165.57%	0.58
VNRXVolitionRx Limited	35.61M	0.29	-0.94	59.1%	-15.54%
BDSXBiodesix, Inc.	66.27M	8.33	-1.26	45.3%	-49.31%	-337.3%	2.97
GRALGRAIL, Inc.	3.8B	97.44	-1.53	34.9%	-286.43%	-18.14%	0.03
GHGuardant Health, Inc.	14.54B	111.98	-31.46	31.04%	-44.18%	-45.84%
ADVBAdvanced Biomed Inc. Common Stock	6.86M	0.32	-67.45		-135.32%	-77.48%	0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	17.1K	13.43K	90.03K	306.39K	775.3K	1.23M
Revenue Growth %	-1%	-	-	-	-	-0.21%	5.7%	2.4%	1.53%	0.59%
Cost of Goods Sold+	0	309.41K	542.48K	639.92K	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	-309.41K	-542.48K	-639.92K	17.1K	13.43K	90.03K	306.39K	775.3K	1.23M
Gross Margin %	-	-	-	-	1%	1%	1%	1%	1%	1%
Gross Profit Growth %	-1%	-	-0.75%	-0.18%	1.03%	-0.21%	5.7%	2.4%	1.53%	0.59%
Operating Expenses+	9.86M	11.91M	15.05M	17.9M	16.06M	21.26M	28.42M	32.09M	36.76M	28.26M
OpEx % of Revenue	-	-	-	-	939.4%	1582.76%	315.69%	104.72%	47.42%	22.91%
Selling, General & Admin	3.9M	5.43M	6.13M	6.95M	5.49M	6.54M	14.83M	16.4M	16.92M	13.64M
SG&A % of Revenue	-	-	-	-	320.84%	486.83%	164.67%	53.54%	21.82%	11.06%
Research & Development	6.1M	6.84M	8.91M	10.91M	10.36M	14.53M	13.02M	15.33M	19.55M	14.41M
R&D % of Revenue	-	-	-	-	606.18%	1081.95%	144.64%	50.04%	25.22%	11.68%
Other Operating Expenses	-15.68K	-361.32K	349.84K	37.23K	211.73K	187.83K	574.39K	348.81K	292.05K	212.43K
Operating Income+	-10.01M	-12.27M	-15.05M	-17.9M	-16.04M	-21.25M	-28.33M	-31.78M	-35.99M	-27.02M
Operating Margin %	-	-	-	-	-938.4%	-1581.76%	-314.69%	-103.72%	-46.42%	-21.91%
Operating Income Growth %	-0.69%	-0.23%	-0.23%	-0.19%	0.1%	-0.32%	-0.33%	-0.12%	-0.13%	0.25%
EBITDA+	-9.77M	-11.96M	-14.5M	-17.26M	-15.14M	-20.21M	-27.19M	-30.59M	-34.57M	-25.69M
EBITDA Margin %	-	-	-	-	-885.62%	-1504.24%	-301.97%	-99.84%	-44.59%	-20.82%
EBITDA Growth %	-0.69%	-0.22%	-0.21%	-0.19%	0.12%	-0.33%	-0.35%	-0.13%	-0.13%	0.26%
D&A (Non-Cash Add-back)	236.34K	309.41K	542.48K	639.92K	902.41K	1.04M	1.15M	1.19M	1.41M	1.34M
EBIT	-9.53M	-11.91M	-14.7M	-17.9M	-15.97M	-20.27M	-26.83M	-30.43M	-35.46M	-26.92M
Net Interest Income+	0	0	0	0	-14.21K	-80.3K	-153.07K	-47.82K	-128.3K	-330.42K
Interest Income	0	0	0	0	112.37K	49.49K	2.73K	125.27K	93.32K	9.95K
Interest Expense	0	0	73.13K	110.92K	126.57K	129.8K	155.8K	173.09K	221.62K	340.36K
Other Income/Expense	470.87K	361.32K	-73.13K	-110.92K	-56.13K	848.52K	1.34M	1.18M	310.62K	-233.01K
Pretax Income+	-9.53M	-11.91M	-14.77M	-18.01M	-16.1M	-20.4M	-26.99M	-30.6M	-35.68M	-27.26M
Pretax Margin %	-	-	-	-	-941.69%	-1518.6%	-299.77%	-99.87%	-46.02%	-22.1%
Income Tax+	-4.6K	0	-276.71K	110.92K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	0.99%	0.99%	0.99%	0.99%
Net Income+	-9.53M	-11.91M	-14.77M	-18.01M	-16.1M	-20.35M	-26.81M	-30.27M	-35.32M	-26.97M
Net Margin %	-	-	-	-	-941.69%	-1515.08%	-297.82%	-98.79%	-45.56%	-21.86%
Net Income Growth %	-0.16%	-0.25%	-0.24%	-0.22%	0.11%	-0.26%	-0.32%	-0.13%	-0.17%	0.24%
Net Income (Continuing)	-9.53M	-11.91M	-14.77M	-18.01M	-16.1M	-20.4M	-26.99M	-30.6M	-35.68M	-27.26M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	-47.18K	-222.29K	-551.97K	-909.97K	-1.2M
EPS (Diluted)+	-0.54	-0.52	-0.56	-0.57	-0.41	-0.45	-0.51	-0.55	-0.50	-0.31
EPS Growth %	0.11%	0.04%	-0.08%	-0.02%	0.28%	-0.1%	-0.13%	-0.08%	0.09%	0.38%
EPS (Basic)	-0.54	-0.52	-0.56	-0.57	-0.41	-0.45	-0.51	-0.55	-0.50	-0.31
Diluted Shares Outstanding	17.73M	23.05M	26.39M	31.39M	39.18M	45.28M	52.66M	55.35M	71.23M	86.53M
Basic Shares Outstanding	17.73M	23.05M	26.39M	31.39M	39.18M	45.28M	52.66M	55.35M	71.23M	86.53M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6.22M	22.01M	10.57M	13.9M	17.56M	20.33M	21.98M	12.17M	21.85M	4.06M
Cash & Short-Term Investments	5.92M	21.68M	10.12M	13.43M	16.97M	19.44M	20.58M	10.87M	20.73M	3.26M
Cash Only	5.92M	21.68M	10.12M	13.43M	16.97M	19.44M	20.58M	10.87M	20.73M	3.26M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	7.12K	12.51K	72.61K	242.62K	110.57K
Days Sales Outstanding	-	-	-	-	-	193.41	50.72	86.5	114.22	32.72
Inventory	0	0	0	0	0	0	598.37K	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	153.72K	166.89K	202.29K	229.75K	322.59K	576.66K	786.64K	447.57K	360.13K	343.14K
Total Non-Current Assets+	1.49M	2.72M	4.06M	3.59M	3.74M	5.82M	5.51M	6.12M	6.1M	5.34M
Property, Plant & Equipment	783.8K	2.12M	3.48M	3.12M	3.36M	5.5M	5.29M	6.01M	6.07M	5.03M
Fixed Asset Turnover	-	-	-	-	0.01x	0.00x	0.02x	0.05x	0.13x	0.25x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	705.38K	602.19K	576.4K	466.9K	372.31K	321.64K	216.88K	110.5K	23.89K	313.75K
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	0	0	0	0
Total Assets+	7.71M	24.73M	14.62M	17.49M	21.29M	26.15M	27.49M	18.3M	27.95M	9.4M
Asset Turnover	-	-	-	-	0.00x	0.00x	0.00x	0.02x	0.03x	0.13x
Asset Growth %	1.25%	2.21%	-0.41%	0.2%	0.22%	0.23%	0.05%	-0.33%	0.53%	-0.66%
Total Current Liabilities+	1.12M	2.03M	2.29M	2.33M	3.86M	6.24M	6.52M	17.39M	8.94M	7.79M
Accounts Payable	323.51K	281.18K	351.74K	807.16K	627.25K	1.54M	1.54M	3.04M	3.21M	2.77M
Days Payables Outstanding	-	331.7	236.66	460.39	-	-	-	-	-	-
Short-Term Debt	81.34K	149.67K	582.99K	561.7K	647.57K	841.32K	797.86K	1.07M	1.21M	860.22K
Deferred Revenue (Current)	219.36K	45.51K	0	40.09K	39.3K	69.22K	12.51K	1000K	106.6K	230K
Other Current Liabilities	-162.68K	-238.03K	-139.08K	-145.15K	-39.3K	-69.22K	0	0	126.65K	97.89K
Current Ratio	5.56x	10.82x	4.61x	5.96x	4.55x	3.26x	3.37x	0.70x	2.44x	0.52x
Quick Ratio	5.56x	10.82x	4.61x	5.96x	4.55x	3.26x	3.28x	0.70x	2.44x	0.52x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	547.87K	1.52M	2.38M	3.02M	3.23M	3.62M	3.25M	4.04M	27.72M	27.72M
Long-Term Debt	0	432.03K	1.31M	2.7M	2.2M	2.61M	2.27M	2.78M	3.62M	3.95M
Capital Lease Obligations	299.86K	889.81K	874.68K	720.01K	739.58K	753.79K	728.39K	836.22K	778.08K	739.02K
Deferred Tax Liabilities	-248.01K	-202.32K	-188.58K	-311.04K	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	-408.97K	0	0	253.22K	420.47K	422.71K	361.24K
Total Liabilities	1.67M	3.56M	4.67M	5.35M	7.09M	9.86M	9.77M	21.42M	36.66M	35.51M
Total Debt+	381.2K	1.47M	2.77M	3.27M	3.94M	4.44M	4.02M	4.97M	5.86M	5.82M
Net Debt	-5.53M	-20.21M	-7.35M	-10.16M	-13.03M	-15M	-16.56M	-5.89M	-14.87M	2.56M
Debt / Equity	0.06x	0.07x	0.28x	0.27x	0.28x	0.27x	0.23x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-205.73x	-161.35x	-126.75x	-163.70x	-181.85x	-183.61x	-162.38x	-79.40x
Total Equity+	6.04M	21.18M	9.96M	12.14M	14.2M	16.29M	17.72M	-3.13M	-8.71M	-26.11M
Equity Growth %	15.42%	2.5%	-0.53%	0.22%	0.17%	0.15%	0.09%	-1.18%	-1.79%	-2%
Book Value per Share	0.34	0.92	0.38	0.39	0.36	0.36	0.34	-0.06	-0.12	-0.30
Total Shareholders' Equity	6.04M	21.18M	9.96M	12.14M	14.2M	16.34M	17.94M	-2.57M	-7.8M	-24.91M
Common Stock	18.76K	26.13K	26.52K	35.34K	41.13K	48.61K	53.77K	57.87K	81.9K	96.1K
Retained Earnings	-29.04M	-40.94M	-55.71M	-73.72M	-89.82M	-110.17M	-136.99M	-167.26M	-202.58M	-229.54M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-84.17K	-193.3K	-129.34K	223.65K	125.67K	-59.98K	148.33K	227.1K	243.94K	385.63K
Minority Interest	0	0	0	0	0	-47.18K	-222.29K	-551.97K	-909.97K	-1.2M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-8.77M	-9.06M	-12.19M	-14.73M	-12.74M	-16.46M	-20.85M	-15.28M	-18.06M	-25.89M
Operating CF Margin %	-	-	-	-	-745.17%	-1225.66%	-231.62%	-49.86%	-23.3%	-20.99%
Operating CF Growth %	-1.12%	-0.03%	-0.35%	-0.21%	0.14%	-0.29%	-0.27%	0.27%	-0.18%	-0.43%
Net Income	-9.53M	-11.91M	-14.77M	-18.01M	-16.1M	-20.4M	-26.99M	-30.6M	-35.68M	-27.26M
Depreciation & Amortization	236.34K	309.41K	528.17K	636.38K	902.41K	1.04M	1.15M	1.19M	1.41M	1.34M
Stock-Based Compensation	1.49M	1.68M	2.44M	2.57M	1.46M	1.73M	5.12M	3.11M	2.29M	1.27M
Deferred Taxes	-339.74K	3.67K	38.94K	403	0	0	0	0	0	0
Other Non-Cash Items	-188.94K	-197.15K	54.51K	22.78K	205.46K	-293.31K	26.17K	0	-224.47K	5.97K
Working Capital Changes	-437.07K	1.05M	-480.74K	45.94K	793.12K	1.46M	-156.11K	11.02M	14.14M	-1.25M
Change in Receivables	0	0	0	0	0	-7.12K	-12.51K	-72.61K	-169.67K	132.04K
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-315.78K	1.09M	-339.66K	65.84K	1.11M	2.05M	522.22K	548.61K	1.22M	-1.22M
Cash from Investing+	-352.24K	-415.09K	-1.43M	-301.81K	-511.27K	-1.65M	-973.56K	-1.57M	-1.08M	-573.85K
Capital Expenditures	-352.24K	-415.09K	-1.43M	-301.81K	-511.27K	-1.94M	-973.56K	-1.57M	-1.08M	-277.5K
CapEx % of Revenue	-	-	-	-	29.91%	144.5%	10.81%	5.12%	1.4%	0.22%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-55K	0	0	0	0	293.31K	0	0	0	-296.35K
Cash from Financing+	12.88M	25.38M	1.97M	17.97M	16.93M	20.62M	22.86M	6.94M	28.98M	8.66M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	161.83K	154.85K	-45.42K	136.2K	-6.54K	-224.92K	-140.58K	-7.69K	-200.66K	-168.15K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.12M	-9.47M	-13.62M	-15.03M	-13.25M	-18.41M	-21.83M	-16.85M	-19.15M	-26.47M
FCF Margin %	-	-	-	-	-775.08%	-1370.16%	-242.43%	-54.99%	-24.7%	-21.46%
FCF Growth %	-1.05%	-0.04%	-0.44%	-0.1%	0.12%	-0.39%	-0.19%	0.23%	-0.14%	-0.38%
FCF per Share	-0.51	-0.41	-0.52	-0.48	-0.34	-0.41	-0.41	-0.30	-0.27	-0.31
FCF Conversion (FCF/Net Income)	0.92x	0.76x	0.83x	0.82x	0.79x	0.81x	0.78x	0.50x	0.51x	0.96x
Interest Paid	7.33K	20.38K	73.13K	110.92K	126.85K	129.8K	155.8K	173.11K	221.62K	340.36K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-297.24%	-87.48%	-94.88%	-162.99%	-122.24%	-133.49%	-157.66%	-414.78%	-	-
Return on Invested Capital (ROIC)	-1472.83%	-1245.43%	-630.42%	-584.73%	-764.14%	-1295.31%	-1735.77%	-	-	-
Gross Margin	-	-	-	-	100%	100%	100%	100%	100%	100%
Net Margin	-	-	-	-	-94168.55%	-151508.34%	-29782.49%	-9879.11%	-4555.53%	-2186.27%
Debt / Equity	0.06x	0.07x	0.28x	0.27x	0.28x	0.27x	0.23x	-	-	-
Interest Coverage	-	-	-205.73x	-161.35x	-126.75x	-163.70x	-181.85x	-183.61x	-162.38x	-79.40x
FCF Conversion	0.92x	0.76x	0.83x	0.82x	0.79x	0.81x	0.78x	0.50x	0.51x	0.96x
Revenue Growth	-100%	-	-	-	-	-21.43%	570.25%	240.3%	153.04%	59.1%

Frequently Asked Questions

Growth & Financials

VolitionRx Limited (VNRX) reported $1.5M in revenue for fiscal year 2024.

VolitionRx Limited (VNRX) grew revenue by 59.1% over the past year. This is strong growth.

VolitionRx Limited (VNRX) reported a net loss of $22.9M for fiscal year 2024.

Dividend & Returns

VolitionRx Limited (VNRX) had negative free cash flow of $19.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

VolitionRx Limited (VNRX) 10-Year Financial Performance & Capital Metrics

VNRX • • Industrial / General

HealthcareDiagnostics & ResearchCancer Diagnostics & Oncology TestingLiquid Biopsy & Circulating Tumor DNA

Revenue $1M +59.1%
EBITDA -$26M +25.7%
Net Income -$27M +23.6%
EPS (Diluted) -0.31 +38.0%
Gross Margin 100%
EBITDA Margin -2082.35% +53.3%
Operating Margin -2190.9% +52.8%
Net Margin -2186.27% +52.0%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -79.40 +51.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 135.3%

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 10 (bottom 10%)
✗Shares diluted 21.5% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y55.64%

5Y135.32%

3Y139.28%

TTM14.48%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM23.41%

EPS CAGR

10Y-

5Y-

3Y-

TTM35.29%

ROCE

10Y Avg-183.84%

5Y Avg-233.28%

3Y Avg-304.68%

Latest-262.18%

Peer Comparison

Liquid Biopsy & Circulating Tumor DNA

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
BIAFbioAffinity Technologies, Inc.	6.39M	1.42	-0.06	269.75%	-217.5%	-165.57%	0.58
VNRXVolitionRx Limited	35.61M	0.29	-0.94	59.1%	-15.54%
BDSXBiodesix, Inc.	66.27M	8.33	-1.26	45.3%	-49.31%	-337.3%	2.97
GRALGRAIL, Inc.	3.8B	97.44	-1.53	34.9%	-286.43%	-18.14%	0.03
GHGuardant Health, Inc.	14.54B	111.98	-31.46	31.04%	-44.18%	-45.84%
ADVBAdvanced Biomed Inc. Common Stock	6.86M	0.32	-67.45		-135.32%	-77.48%	0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	17.1K	13.43K	90.03K	306.39K	775.3K	1.23M
Revenue Growth %	-1%	-	-	-	-	-0.21%	5.7%	2.4%	1.53%	0.59%
Cost of Goods Sold+	0	309.41K	542.48K	639.92K	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	-309.41K	-542.48K	-639.92K	17.1K	13.43K	90.03K	306.39K	775.3K	1.23M
Gross Margin %	-	-	-	-	1%	1%	1%	1%	1%	1%
Gross Profit Growth %	-1%	-	-0.75%	-0.18%	1.03%	-0.21%	5.7%	2.4%	1.53%	0.59%
Operating Expenses+	9.86M	11.91M	15.05M	17.9M	16.06M	21.26M	28.42M	32.09M	36.76M	28.26M
OpEx % of Revenue	-	-	-	-	939.4%	1582.76%	315.69%	104.72%	47.42%	22.91%
Selling, General & Admin	3.9M	5.43M	6.13M	6.95M	5.49M	6.54M	14.83M	16.4M	16.92M	13.64M
SG&A % of Revenue	-	-	-	-	320.84%	486.83%	164.67%	53.54%	21.82%	11.06%
Research & Development	6.1M	6.84M	8.91M	10.91M	10.36M	14.53M	13.02M	15.33M	19.55M	14.41M
R&D % of Revenue	-	-	-	-	606.18%	1081.95%	144.64%	50.04%	25.22%	11.68%
Other Operating Expenses	-15.68K	-361.32K	349.84K	37.23K	211.73K	187.83K	574.39K	348.81K	292.05K	212.43K
Operating Income+	-10.01M	-12.27M	-15.05M	-17.9M	-16.04M	-21.25M	-28.33M	-31.78M	-35.99M	-27.02M
Operating Margin %	-	-	-	-	-938.4%	-1581.76%	-314.69%	-103.72%	-46.42%	-21.91%
Operating Income Growth %	-0.69%	-0.23%	-0.23%	-0.19%	0.1%	-0.32%	-0.33%	-0.12%	-0.13%	0.25%
EBITDA+	-9.77M	-11.96M	-14.5M	-17.26M	-15.14M	-20.21M	-27.19M	-30.59M	-34.57M	-25.69M
EBITDA Margin %	-	-	-	-	-885.62%	-1504.24%	-301.97%	-99.84%	-44.59%	-20.82%
EBITDA Growth %	-0.69%	-0.22%	-0.21%	-0.19%	0.12%	-0.33%	-0.35%	-0.13%	-0.13%	0.26%
D&A (Non-Cash Add-back)	236.34K	309.41K	542.48K	639.92K	902.41K	1.04M	1.15M	1.19M	1.41M	1.34M
EBIT	-9.53M	-11.91M	-14.7M	-17.9M	-15.97M	-20.27M	-26.83M	-30.43M	-35.46M	-26.92M
Net Interest Income+	0	0	0	0	-14.21K	-80.3K	-153.07K	-47.82K	-128.3K	-330.42K
Interest Income	0	0	0	0	112.37K	49.49K	2.73K	125.27K	93.32K	9.95K
Interest Expense	0	0	73.13K	110.92K	126.57K	129.8K	155.8K	173.09K	221.62K	340.36K
Other Income/Expense	470.87K	361.32K	-73.13K	-110.92K	-56.13K	848.52K	1.34M	1.18M	310.62K	-233.01K
Pretax Income+	-9.53M	-11.91M	-14.77M	-18.01M	-16.1M	-20.4M	-26.99M	-30.6M	-35.68M	-27.26M
Pretax Margin %	-	-	-	-	-941.69%	-1518.6%	-299.77%	-99.87%	-46.02%	-22.1%
Income Tax+	-4.6K	0	-276.71K	110.92K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	0.99%	0.99%	0.99%	0.99%
Net Income+	-9.53M	-11.91M	-14.77M	-18.01M	-16.1M	-20.35M	-26.81M	-30.27M	-35.32M	-26.97M
Net Margin %	-	-	-	-	-941.69%	-1515.08%	-297.82%	-98.79%	-45.56%	-21.86%
Net Income Growth %	-0.16%	-0.25%	-0.24%	-0.22%	0.11%	-0.26%	-0.32%	-0.13%	-0.17%	0.24%
Net Income (Continuing)	-9.53M	-11.91M	-14.77M	-18.01M	-16.1M	-20.4M	-26.99M	-30.6M	-35.68M	-27.26M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	-47.18K	-222.29K	-551.97K	-909.97K	-1.2M
EPS (Diluted)+	-0.54	-0.52	-0.56	-0.57	-0.41	-0.45	-0.51	-0.55	-0.50	-0.31
EPS Growth %	0.11%	0.04%	-0.08%	-0.02%	0.28%	-0.1%	-0.13%	-0.08%	0.09%	0.38%
EPS (Basic)	-0.54	-0.52	-0.56	-0.57	-0.41	-0.45	-0.51	-0.55	-0.50	-0.31
Diluted Shares Outstanding	17.73M	23.05M	26.39M	31.39M	39.18M	45.28M	52.66M	55.35M	71.23M	86.53M
Basic Shares Outstanding	17.73M	23.05M	26.39M	31.39M	39.18M	45.28M	52.66M	55.35M	71.23M	86.53M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6.22M	22.01M	10.57M	13.9M	17.56M	20.33M	21.98M	12.17M	21.85M	4.06M
Cash & Short-Term Investments	5.92M	21.68M	10.12M	13.43M	16.97M	19.44M	20.58M	10.87M	20.73M	3.26M
Cash Only	5.92M	21.68M	10.12M	13.43M	16.97M	19.44M	20.58M	10.87M	20.73M	3.26M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	7.12K	12.51K	72.61K	242.62K	110.57K
Days Sales Outstanding	-	-	-	-	-	193.41	50.72	86.5	114.22	32.72
Inventory	0	0	0	0	0	0	598.37K	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	153.72K	166.89K	202.29K	229.75K	322.59K	576.66K	786.64K	447.57K	360.13K	343.14K
Total Non-Current Assets+	1.49M	2.72M	4.06M	3.59M	3.74M	5.82M	5.51M	6.12M	6.1M	5.34M
Property, Plant & Equipment	783.8K	2.12M	3.48M	3.12M	3.36M	5.5M	5.29M	6.01M	6.07M	5.03M
Fixed Asset Turnover	-	-	-	-	0.01x	0.00x	0.02x	0.05x	0.13x	0.25x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	705.38K	602.19K	576.4K	466.9K	372.31K	321.64K	216.88K	110.5K	23.89K	313.75K
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	0	0	0	0
Total Assets+	7.71M	24.73M	14.62M	17.49M	21.29M	26.15M	27.49M	18.3M	27.95M	9.4M
Asset Turnover	-	-	-	-	0.00x	0.00x	0.00x	0.02x	0.03x	0.13x
Asset Growth %	1.25%	2.21%	-0.41%	0.2%	0.22%	0.23%	0.05%	-0.33%	0.53%	-0.66%
Total Current Liabilities+	1.12M	2.03M	2.29M	2.33M	3.86M	6.24M	6.52M	17.39M	8.94M	7.79M
Accounts Payable	323.51K	281.18K	351.74K	807.16K	627.25K	1.54M	1.54M	3.04M	3.21M	2.77M
Days Payables Outstanding	-	331.7	236.66	460.39	-	-	-	-	-	-
Short-Term Debt	81.34K	149.67K	582.99K	561.7K	647.57K	841.32K	797.86K	1.07M	1.21M	860.22K
Deferred Revenue (Current)	219.36K	45.51K	0	40.09K	39.3K	69.22K	12.51K	1000K	106.6K	230K
Other Current Liabilities	-162.68K	-238.03K	-139.08K	-145.15K	-39.3K	-69.22K	0	0	126.65K	97.89K
Current Ratio	5.56x	10.82x	4.61x	5.96x	4.55x	3.26x	3.37x	0.70x	2.44x	0.52x
Quick Ratio	5.56x	10.82x	4.61x	5.96x	4.55x	3.26x	3.28x	0.70x	2.44x	0.52x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	547.87K	1.52M	2.38M	3.02M	3.23M	3.62M	3.25M	4.04M	27.72M	27.72M
Long-Term Debt	0	432.03K	1.31M	2.7M	2.2M	2.61M	2.27M	2.78M	3.62M	3.95M
Capital Lease Obligations	299.86K	889.81K	874.68K	720.01K	739.58K	753.79K	728.39K	836.22K	778.08K	739.02K
Deferred Tax Liabilities	-248.01K	-202.32K	-188.58K	-311.04K	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	-408.97K	0	0	253.22K	420.47K	422.71K	361.24K
Total Liabilities	1.67M	3.56M	4.67M	5.35M	7.09M	9.86M	9.77M	21.42M	36.66M	35.51M
Total Debt+	381.2K	1.47M	2.77M	3.27M	3.94M	4.44M	4.02M	4.97M	5.86M	5.82M
Net Debt	-5.53M	-20.21M	-7.35M	-10.16M	-13.03M	-15M	-16.56M	-5.89M	-14.87M	2.56M
Debt / Equity	0.06x	0.07x	0.28x	0.27x	0.28x	0.27x	0.23x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-205.73x	-161.35x	-126.75x	-163.70x	-181.85x	-183.61x	-162.38x	-79.40x
Total Equity+	6.04M	21.18M	9.96M	12.14M	14.2M	16.29M	17.72M	-3.13M	-8.71M	-26.11M
Equity Growth %	15.42%	2.5%	-0.53%	0.22%	0.17%	0.15%	0.09%	-1.18%	-1.79%	-2%
Book Value per Share	0.34	0.92	0.38	0.39	0.36	0.36	0.34	-0.06	-0.12	-0.30
Total Shareholders' Equity	6.04M	21.18M	9.96M	12.14M	14.2M	16.34M	17.94M	-2.57M	-7.8M	-24.91M
Common Stock	18.76K	26.13K	26.52K	35.34K	41.13K	48.61K	53.77K	57.87K	81.9K	96.1K
Retained Earnings	-29.04M	-40.94M	-55.71M	-73.72M	-89.82M	-110.17M	-136.99M	-167.26M	-202.58M	-229.54M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-84.17K	-193.3K	-129.34K	223.65K	125.67K	-59.98K	148.33K	227.1K	243.94K	385.63K
Minority Interest	0	0	0	0	0	-47.18K	-222.29K	-551.97K	-909.97K	-1.2M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-8.77M	-9.06M	-12.19M	-14.73M	-12.74M	-16.46M	-20.85M	-15.28M	-18.06M	-25.89M
Operating CF Margin %	-	-	-	-	-745.17%	-1225.66%	-231.62%	-49.86%	-23.3%	-20.99%
Operating CF Growth %	-1.12%	-0.03%	-0.35%	-0.21%	0.14%	-0.29%	-0.27%	0.27%	-0.18%	-0.43%
Net Income	-9.53M	-11.91M	-14.77M	-18.01M	-16.1M	-20.4M	-26.99M	-30.6M	-35.68M	-27.26M
Depreciation & Amortization	236.34K	309.41K	528.17K	636.38K	902.41K	1.04M	1.15M	1.19M	1.41M	1.34M
Stock-Based Compensation	1.49M	1.68M	2.44M	2.57M	1.46M	1.73M	5.12M	3.11M	2.29M	1.27M
Deferred Taxes	-339.74K	3.67K	38.94K	403	0	0	0	0	0	0
Other Non-Cash Items	-188.94K	-197.15K	54.51K	22.78K	205.46K	-293.31K	26.17K	0	-224.47K	5.97K
Working Capital Changes	-437.07K	1.05M	-480.74K	45.94K	793.12K	1.46M	-156.11K	11.02M	14.14M	-1.25M
Change in Receivables	0	0	0	0	0	-7.12K	-12.51K	-72.61K	-169.67K	132.04K
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-315.78K	1.09M	-339.66K	65.84K	1.11M	2.05M	522.22K	548.61K	1.22M	-1.22M
Cash from Investing+	-352.24K	-415.09K	-1.43M	-301.81K	-511.27K	-1.65M	-973.56K	-1.57M	-1.08M	-573.85K
Capital Expenditures	-352.24K	-415.09K	-1.43M	-301.81K	-511.27K	-1.94M	-973.56K	-1.57M	-1.08M	-277.5K
CapEx % of Revenue	-	-	-	-	29.91%	144.5%	10.81%	5.12%	1.4%	0.22%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-55K	0	0	0	0	293.31K	0	0	0	-296.35K
Cash from Financing+	12.88M	25.38M	1.97M	17.97M	16.93M	20.62M	22.86M	6.94M	28.98M	8.66M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	161.83K	154.85K	-45.42K	136.2K	-6.54K	-224.92K	-140.58K	-7.69K	-200.66K	-168.15K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.12M	-9.47M	-13.62M	-15.03M	-13.25M	-18.41M	-21.83M	-16.85M	-19.15M	-26.47M
FCF Margin %	-	-	-	-	-775.08%	-1370.16%	-242.43%	-54.99%	-24.7%	-21.46%
FCF Growth %	-1.05%	-0.04%	-0.44%	-0.1%	0.12%	-0.39%	-0.19%	0.23%	-0.14%	-0.38%
FCF per Share	-0.51	-0.41	-0.52	-0.48	-0.34	-0.41	-0.41	-0.30	-0.27	-0.31
FCF Conversion (FCF/Net Income)	0.92x	0.76x	0.83x	0.82x	0.79x	0.81x	0.78x	0.50x	0.51x	0.96x
Interest Paid	7.33K	20.38K	73.13K	110.92K	126.85K	129.8K	155.8K	173.11K	221.62K	340.36K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-297.24%	-87.48%	-94.88%	-162.99%	-122.24%	-133.49%	-157.66%	-414.78%	-	-
Return on Invested Capital (ROIC)	-1472.83%	-1245.43%	-630.42%	-584.73%	-764.14%	-1295.31%	-1735.77%	-	-	-
Gross Margin	-	-	-	-	100%	100%	100%	100%	100%	100%
Net Margin	-	-	-	-	-94168.55%	-151508.34%	-29782.49%	-9879.11%	-4555.53%	-2186.27%
Debt / Equity	0.06x	0.07x	0.28x	0.27x	0.28x	0.27x	0.23x	-	-	-
Interest Coverage	-	-	-205.73x	-161.35x	-126.75x	-163.70x	-181.85x	-183.61x	-162.38x	-79.40x
FCF Conversion	0.92x	0.76x	0.83x	0.82x	0.79x	0.81x	0.78x	0.50x	0.51x	0.96x
Revenue Growth	-100%	-	-	-	-	-21.43%	570.25%	240.3%	153.04%	59.1%

Frequently Asked Questions

Growth & Financials

VolitionRx Limited (VNRX) reported $1.5M in revenue for fiscal year 2024.

VolitionRx Limited (VNRX) grew revenue by 59.1% over the past year. This is strong growth.

VolitionRx Limited (VNRX) reported a net loss of $22.9M for fiscal year 2024.

Dividend & Returns

VolitionRx Limited (VNRX) had negative free cash flow of $19.7M in fiscal year 2024, likely due to heavy capital investments.